X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (117) 117
male (78) 78
middle aged (73) 73
female (71) 71
oncology (67) 67
adult (59) 59
aged (56) 56
hematology (38) 38
treatment outcome (23) 23
karyotyping (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
prognosis (19) 19
adolescent (17) 17
chromosome aberrations (17) 17
genetics & heredity (16) 16
chemotherapy (15) 15
cancer (14) 14
aged, 80 and over (12) 12
cells, cultured (12) 12
follow-up studies (12) 12
leukemia, myeloid, acute - genetics (12) 12
survival rate (12) 12
therapy (12) 12
time factors (12) 12
animals (11) 11
leukemia (11) 11
remission induction (11) 11
survival analysis (11) 11
acute disease (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
bone-marrow (10) 10
expression (10) 10
index medicus (10) 10
mice (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
disease-free survival (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - genetics (8) 8
transplantation (8) 8
cyclophosphamide - administration & dosage (7) 7
disease progression (7) 7
drug administration schedule (7) 7
drug evaluation (7) 7
immunohistochemistry (7) 7
in situ hybridization, fluorescence (7) 7
leukemia - genetics (7) 7
leukemia, myeloid - genetics (7) 7
lung neoplasms - drug therapy (7) 7
research (7) 7
risk factors (7) 7
survival (7) 7
vincristine - administration & dosage (7) 7
angiogenesis (6) 6
bone marrow - pathology (6) 6
carcinoma (6) 6
chronic myelogenous leukemia (6) 6
cisplatin (6) 6
clinical-trials (6) 6
further section · weitere sektionen (6) 6
immunophenotyping (6) 6
leukemia - pathology (6) 6
medicine & public health (6) 6
myelodysplastic syndromes - genetics (6) 6
non-hodgkins-lymphoma (6) 6
receptor (6) 6
young adult (6) 6
acute myelogenous leukemia (5) 5
acute nonlymphocytic leukemia (5) 5
antigens, cd - metabolism (5) 5
cell division - drug effects (5) 5
cells (5) 5
chromosome disorders (5) 5
chronic-phase (5) 5
colony-forming units assay (5) 5
cytarabine - administration & dosage (5) 5
cytogenetic analysis (5) 5
differentiation (5) 5
dose-response relationship, drug (5) 5
endothelial growth-factor (5) 5
etoposide - administration & dosage (5) 5
flow cytometry (5) 5
fluorouracil (5) 5
hematopoietic stem cells - pathology (5) 5
hematopoietic stem cells - physiology (5) 5
in-situ hybridization (5) 5
interferon-alpha - administration & dosage (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - pathology (5) 5
lung neoplasms - pathology (5) 5
medicine, research & experimental (5) 5
neoplasms - therapy (5) 5
phenotype (5) 5
polymerase chain reaction (5) 5
precursor cell lymphoblastic leukemia-lymphoma - genetics (5) 5
recombinant proteins (5) 5
tumor angiogenesis (5) 5
vegf (5) 5
ac133 antigen (4) 4
acute myeloid-leukemia (4) 4
bone marrow - metabolism (4) 4
bone marrow transplantation (4) 4
breast-cancer (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 12, pp. 1634 - 1642
Journal Article
1990, 5th ed. --, ISBN 3540527699, xiv, 391
Book
1995, Recent results in cancer research, ISBN 9783540576297, Volume 138., ix, 176
Book
Journal Article
Blood, ISSN 0006-4971, 08/2004, Volume 104, Issue 3, pp. 626 - 633
Journal Article
1987, 4th ed., fully rev., ISBN 9783540173670, xvii, 372
Book
Journal Article
Blood, ISSN 0006-4971, 12/2007, Volume 110, Issue 13, pp. 4618 - 4619
Journal Article
BLOOD, ISSN 0006-4971, 05/2000, Volume 95, Issue 10, pp. 3106 - 3112
Recent findings support the hypothesis that the CD34(+)-cell population in bone marrow and peripheral blood contains hematopoietic and endothelial progenitor... 
ANGIOGENESIS | LETHALITY | VASCULOGENESIS | BONE-MARROW | MONOCLONAL-ANTIBODY | GROWTH-FACTOR | RECEPTORS | HEMATOLOGY | EXPRESSION | HEMATOPOIETIC STEM | BLOOD | Antigens, CD34 | Endothelium, Vascular - cytology | Immunohistochemistry | Animals | Flow Cytometry | Hematopoietic Stem Cells - cytology | Humans | Cells, Cultured | Cell Differentiation | Mice | Hematopoietic Stem Cell Mobilization
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 2006, Volume 6, Issue 1, pp. 285 - 285
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2014, Volume 93, Issue 1, pp. 71 - 80
Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed... 
Medicine & Public Health | Hematology | Young adults and adolescents | Oncology | Accelerated phase | Blast crisis | Chronic myeloid leukemia | DIAGNOSIS | ADULTS | CANCER | TYROSINE KINASE INHIBITORS | IMPACT | Chronicmyeloid leukemia | THERAPY | ADOLESCENTS | CLINICAL-TRIALS | IMATINIB | HEMATOLOGY | AGE | Piperazines - administration & dosage | Age Factors | Follow-Up Studies | Humans | Middle Aged | Male | RNA, Neoplasm - blood | Young Adult | Benzamides - administration & dosage | Benzamides - therapeutic use | Karnofsky Performance Status | Fusion Proteins, bcr-abl - blood | Splenomegaly - etiology | Adult | Female | Randomized Controlled Trials as Topic - statistics & numerical data | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | RNA, Messenger - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Aged | Leukemia, Myeloid, Chronic-Phase - genetics | Hemoglobin | Research | Analysis | Oncology, Experimental | Cancer | Original
Journal Article
Experimental Cell Research, ISSN 0014-4827, 2004, Volume 300, Issue 1, pp. 65 - 71
Bone-marrow-derived, circulating endothelial precursor cells contribute to neoangiogenesis in various diseases. Rapamycin has recently been shown to have... 
Neoangiogenesis | Rapamycin | Endothelial progenitor cells | ACTIVATION | neoangiogenesis | MECHANISMS | TUMOR ANGIOGENESIS | IDENTIFICATION | CANCER | CELL BIOLOGY | SIGNAL-TRANSDUCTION | ONCOLOGY | endothelial progenitor cells | GROWTH-FACTOR | HEMANGIOBLAST | PRECURSOR CELLS | EXPRESSION | rapamycin | Protein Kinases - metabolism | Stem Cells - immunology | Immunosuppressive Agents | Apoptosis - drug effects | von Willebrand Factor - immunology | Humans | Stem Cells - cytology | RNA, Messenger - metabolism | Cell Culture Techniques - methods | Dose-Response Relationship, Drug | Cell Division - immunology | Tacrolimus - pharmacology | Neovascularization, Pathologic - physiopathology | RNA, Messenger - drug effects | Protein Kinases - drug effects | Sirolimus - therapeutic use | Antigens - drug effects | Cell Separation | Jurkat Cells | Peptides - immunology | Cells, Cultured | Cell Adhesion - drug effects | AC133 Antigen | Sirolimus - pharmacology | Cell Division - drug effects | Cell Adhesion - immunology | Endothelial Cells - immunology | Cell Differentiation - immunology | Glycoproteins - immunology | Cell Differentiation - drug effects | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | HL-60 Cells | Stem Cells - drug effects | Antigens - immunology | TOR Serine-Threonine Kinases | Apoptosis - physiology | Antigens, CD | Endothelial Cells - drug effects
Journal Article
Deutsches Arzteblatt, ISSN 0012-1207, 07/2008, Volume 105, Issue 27, pp. 492 - 497
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.